{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:08:52Z","timestamp":1759972132798,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.braindev.2023.03.003","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T08:59:49Z","timestamp":1680166789000},"page":"360-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treating neurodegenerative disease: Nusinersen and other therapeutic strategies for improved motor function"],"prefix":"10.1016","volume":"45","author":[{"given":"Kristine P.","family":"Pashin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tejas C.","family":"Sekhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.braindev.2023.03.003_b0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.braindev.2022.11.002","article-title":"Muscle impairment in MRI affect variability in treatment response to nusinersen in patients with spinal muscular atrophy type 2 and 3: A retrospective cohort study","volume":"45","author":"Shimizu-Motohashi","year":"2023","journal-title":"Brain Dev"},{"issue":"3","key":"10.1016\/j.braindev.2023.03.003_b0010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/cells11030417","article-title":"Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy","volume":"11","author":"Aslesh","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.braindev.2023.03.003_b0015","first-page":"194","article-title":"Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy","volume":"24","author":"Neil","year":"2019","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.braindev.2023.03.003_b0020","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s13023-022-02547-8","article-title":"Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study","volume":"17","author":"Pechmann","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.braindev.2023.03.003_b0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s42466-021-00162-9","article-title":"Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders","volume":"4","author":"Jablonka","year":"2022","journal-title":"Neurol Res Pract"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760423000463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760423000463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:51:28Z","timestamp":1759953088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760423000463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S0387760423000463"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2023.03.003","relation":{},"ISSN":["0387-7604"],"issn-type":[{"type":"print","value":"0387-7604"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating neurodegenerative disease: Nusinersen and other therapeutic strategies for improved motor function","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2023.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of The Japanese Society of Child Neurology. All rights reserved.","name":"copyright","label":"Copyright"}]}}